855 related articles for article (PubMed ID: 16914971)
1. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
3. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
4. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
7. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
9. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
11. [New drugs; natalizumab].
van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
[TBL] [Abstract][Full Text] [Related]
12. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
14. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
Hartung HP
Lancet Neurol; 2009 Jan; 8(1):28-31. PubMed ID: 19081511
[No Abstract] [Full Text] [Related]
15. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
Kleinschmidt-DeMasters BK; Tyler KL
N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
Berger JR; Koralnik IJ
N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
[No Abstract] [Full Text] [Related]
17. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab: bench to bedside and beyond.
Rudick R; Polman C; Clifford D; Miller D; Steinman L
JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
[TBL] [Abstract][Full Text] [Related]
19. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
